文献速递消化系统肿瘤

BRAFV600E结直肠癌获得性耐药异质性的趋同治疗策略

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.
PubMed 文献 · Cancer Discov · 2018-02-05

该研究对接受BRAF抑制剂联合治疗的BRAFV600E结直肠癌患者配对肿瘤活检进行全外显子测序,并对cfDNA进行靶向测序,鉴定出14种驱动获得性耐药的MAPK通路改变,单例患者最多达8种。研究建立pooled clone系统追踪耐药克隆扩增,发现ERK抑制尤其联合BRAF与EGFR抑制可显著阻断克隆扩增。

要点

  • BRAFV600E结直肠癌获得性耐药由MAPK通路多种异质性改变驱动
  • 单例患者可同时检出多个耐药改变
  • ERK抑制联合BRAF与EGFR抑制可能抑制异质性克隆扩增

核心结论

  • BRAFV600E结直肠癌获得性耐药由MAPK通路异质性改变驱动,趋同的 upfront 联合治疗可能抑制异质性克隆扩增。

研究设计与样本

  • 对接受BRAF抑制剂联合治疗的BRAFV600E结直肠癌患者配对肿瘤活检行全外显子测序,并对cfDNA行靶向测序。
  • 建立pooled clone系统,在体外和体内研究获得性耐药期间的克隆扩增。

主要发现

  • 鉴定出14种驱动获得性耐药的MAPK通路组分改变,单例患者最多存在8种改变。
  • 体外可从培养上清cfDNA实时监测单个耐药克隆的动态。
  • BRAF、EGFR和MEK抑制剂联合治疗期间观察到多个耐药克隆扩增。
  • ERK抑制尤其联合BRAF和EGFR抑制,在体外和体内显著阻断克隆扩增。

临床怎么用

  • 提示对BRAFV600E结直肠癌可考虑趋同的 upfront 联合策略以拦截多种耐药机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clonal heterogeneity associated with acquired resistance presents a critical therapeutic challenge. Whole-exome sequencing of paired tumor biopsies and targeted sequencing of cell-free DNA (cfDNA) from patients with BRAFV600E colorectal cancer receiving BRAF inhibitor combinations identified 14 distinct alterations in MAPK pathway components driving acquired resistance, with as many as eight alterations in a single patient. We developed a pooled clone system to study clonal outgrowth during acquired resistance, in vitro and in vivoIn vitro, the dynamics of individual resistant clones could be monitored in real time in cfDNA isolated from culture media during therapy. Outgrowth of multiple resistant clones was observed during therapy with BRAF, EGFR, and MEK inhibitor combinations. However, ERK inhibition, particularly in combination with BRAF and EGFR inhibition, markedly abrogated clonal outgrowth in vitro and in vivo Thus, convergent, up-front therapy may suppress outgrowth of heterogeneous clones harboring clinically observed resistance alterations, which may improve clinical outcome.Significance: We observed heterogeneous, recurrent alterations in the MAPK pathway as key drivers of acquired resistance in BRAFV600E colorectal cancer, with multiple concurrent resistance alterations detectable in individual patients. Using a novel pooled clone system, we identify convergent up-front therapeutic strategies capable of intercepting multiple resistance mechanisms as potential approaches to suppress emergence of acquired resistance. Cancer Discov; 8(4); 417-27. ©2018 AACR.See related commentary by Janku, p. 389See related article by Corcoran et al., p. 428This article is highlighted in the In This Issue feature, p. 371.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hazar-Rethinam M, Kleyman M, Han GC, et al. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018. PMID: 29431697. doi:10.1158/2159-8290.CD-17-1227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。